Welcome to the Official Website of the ALBINO-Study

While the EU-funding period has come to an end in June 2025, huge progress can be reported in the ALBINO-study:

382 cerebral MRIs of 393 cMRIs performed in study participants (97%) have been filed in the ALBINO biomarker database and centrally rated.

387 out of 458 (amplitude-integrated) EEGs performed in study participants (84%) have been filed in the ALBINO biomarker database.

These biomarkers will help to assess efficacy of the study intervention and enable deeper research into early classification of asphyxiated infants, potentially resulting in even better targeted clinical trials in the future.

Most importantly, 384 out of 445 study participants who reached 2 years of age (86.2%), have fully documented primary outcome in the ALBINO database. While some participants unfortunately have been lost over the years (~6%), the international ALBINO collaboration makes every possible effort to complete follow-up in as many participants as possible. Follow-up for ALBINO participants will be ongoing at least until March 2026.

Parents of study participants are asked to please answer contact requests from their respective study sites and report outcomes!

At this point of the project, The ALBINO Consortium expresses its heartfelt gratefulness towards the European Union and its representatives, for funding and for their understanding of the complexity of this difficult project and their patience!